Efficacy of c-Met inhibitor for advanced prostate cancer

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Tu, William H ^a   Zhu, Chunfang ^a   Clark, Curtis ^a   Christensen, James G ^b   Sun, Zijie ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [1 (2,6 DICHLORO 3 FLUOROPHENYL)ETHOXY] 5 [1 (4 PIPERIDINYL) 1H PYRAZOL 4 YL] 2 PYRIDINYLAMINE; 5 (2,6 DICHLOROBENZYLSULFONYL) 3 [3,5 DIMETHYL 4 [2 (1 PYRROLIDINYLMETHYL) 1 PYRROLIDINYLCARBONYL] 1H PYRROL 2 YLMETHYLENE] 1,3 DIHYDRO 2H INDOL 2 ONE; ANDROGEN; SCATTER FACTOR RECEPTOR; 5 ((2,6 DICHLOROBENZYL)SULFONYL) 3 ((3,5 DIMETHYL 4 ((2 (PYRROLIDIN 1 YLMETHYL)PYRROLIDIN 1 YL)CARBONYL) 1H PYRROL 2 YL)METHYLENE) 1,3 DIHYDRO 2H INDOL 2 ONE; 5-((2,6-DICHLOROBENZYL)SULFONYL)-3-((3,5-DIMETHYL-4-((2-(PYRROLIDIN-1-YLMETHYL)PYRROLIDIN-1-YL)CARBONYL)-1H-PYRROL-2-YL)METHYLENE)-1,3-DIHYDRO-2H-INDOL-2-ONE; INDOLE DERIVATIVE; PF-2341066; PIPERIDINE DERIVATIVE; PYRIDINE DERIVATIVE; SULFONE;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CASTRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; TUMOR XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; CHEMISTRY; DISEASE MODEL; DRUG ANTAGONISM; DRUG SCREENING; GENE EXPRESSION REGULATION; MALE; METABOLISM; PHOSPHORYLATION; PROSTATE TUMOR; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INDOLES; MALE; MICE; NEOPLASM TRANSPLANTATION; PHOSPHORYLATION; PIPERIDINES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MET; PYRIDINES; SIGNAL TRANSDUCTION; SULFONES;

EID: 77957774165     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-556     Document Type: Article

References (40)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009, 59(4):225-249. 10.3322/caac.20006, 19474385.
2. Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 2007, 13(21):6396-6403. 10.1158/1078-0432.CCR-07-1036, 17975152.
3. Balk SP. Androgen receptor as a target in androgen-independent prostate cancer. Urology 2002, 60(3 Suppl 1):132-138. discussion 138-139, 10.1016/S0090-4295(02)01593-5, 12231070.
4. Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol 2002, 20(13):3001-3015. 10.1200/JCO.2002.10.018, 12089231.
5. So A, Gleave M, Hurtado-Col A, Nelson C. Mechanisms of the development of androgen independence in prostate cancer. World J Urol 2005, 23(1):1-9. 10.1007/s00345-004-0473-1, 15770516.
6. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande Woude GF, Aaronson SA. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991, 251(4995):802-804. 10.1126/science.1846706, 1846706.
7. Knudsen BS, Edlund M. Prostate cancer and the met hepatocyte growth factor receptor. Adv Cancer Res 2004, 91:31-67. full_text, 15327888.
8. Humphrey PA, Zhu X, Zarnegar R, Swanson PE, Ratliff TL, Vollmer RT, Day ML. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 1995, 147(2):386-396. 1869824, 7639332.
9. Kasai S, Sugimura K, Matsumoto K, Nishi N, Kishimoto T, Nakamura T. Hepatocyte growth factor is a paracrine regulator of rat prostate epithelial growth. Biochem Biophys Res Commun 1996, 228(2):646-652. 10.1006/bbrc.1996.1710, 8920963.
10. Knudsen BS, Gmyrek GA, Inra J, Scherr DS, Vaughan ED, Nanus DM, Kattan MW, Gerald WL, Vande Woude GF. High expression of the Met receptor in prostate cancer metastasis to bone. Urology 2002, 60(6):1113-1117. 10.1016/S0090-4295(02)01954-4, 12475693.
11. Verras M, Lee J, Xue H, Li TH, Wang Y, Sun Z. The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. Cancer Res 2007, 67(3):967-975. 10.1158/0008-5472.CAN-06-3552, 17283128.
12. Christensen JG, Schreck R, Burrows J, Kuruganti P, Chan E, Le P, Chen J, Wang X, Ruslim L, Blake R, et al. A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 2003, 63(21):7345-7355.
13. Smolen GA, Sordella R, Muir B, Mohapatra G, Barmettler A, Archibald H, Kim WJ, Okimoto RA, Bell DW, Sgroi DC, et al. Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. Proc Natl Acad Sci USA 2006, 103(7):2316-2321. 10.1073/pnas.0508776103, 1413705, 16461907.
14. Zou HY, Li Q, Lee JH, Arango ME, McDonnell SR, Yamazaki S, Koudriakova TB, Alton G, Cui JJ, Kung PP, et al. An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 2007, 67(9):4408-4417. 10.1158/0008-5472.CAN-06-4443, 17483355.
15. Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR, Yamazaki S, Alton GR, Mroczkowski B, Los G. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 2007, 6(12 Pt 1):3314-3322. 10.1158/1535-7163.MCT-07-0365, 18089725.
16. Yang Y, Wislez M, Fujimoto N, Prudkin L, Izzo JG, Uno F, Ji L, Hanna AE, Langley RR, Liu D, et al. A selective small molecule inhibitor of c-Met, PHA-665752, reverses lung premalignancy induced by mutant K-ras. Mol Cancer Ther 2008, 7(4):952-960. 10.1158/1535-7163.MCT-07-2045, 18413809.
17. Klein KA, Reiter RE, Redula J, Moradi H, Zhu XL, Brothman AR, Lamb DJ, Marcelli M, Belldegrun A, Witte ON, et al. Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med 1997, 3(4):402-408. 10.1038/nm0497-402, 9095173.
18. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC, Chung LW. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 1994, 54(10):2577-2581.
19. Tepper CG, Boucher DL, Ryan PE, Ma AH, Xia L, Lee LF, Pretlow TG, Kung HJ. Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Res 2002, 62(22):6606-6614.
20. Adam RM, Orsola A, Freeman MR. A novel method for implantation of LNCaP prostate tumor cells under the renal capsule. In Vitro Cell Dev Biol Anim 2001, 37(6):360-362.
21. Wang Y, Xue H, Cutz JC, Bayani J, Mawji NR, Chen WG, Goetz LJ, Hayward SW, Sadar MD, Gilks CB, et al. An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. Lab Invest 2005, 85(11):1392-1404. 10.1038/labinvest.3700335, 16155594.
22. Gleave ME, Hsieh JT, Wu HC, von Eschenbach AC, Chung LW. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res 1992, 52(6):1598-1605.
23. Sato N, Gleave ME, Bruchovsky N, Rennie PS, Beraldi E, Sullivan LD. A metastatic and androgen-sensitive human prostate cancer model using intraprostatic inoculation of LNCaP cells in SCID mice. Cancer Res 1997, 57(8):1584-1589.
24. Stephenson RA, Dinney CP, Gohji K, Ordonez NG, Killion JJ, Fidler IJ. Metastatic model for human prostate cancer using orthotopic implantation in nude mice. J Natl Cancer Inst 1992, 84(12):951-957. 10.1093/jnci/84.12.951, 1378502.
25. Rembrink K, Romijn JC, van der Kwast TH, Rubben H, Schroder FH. Orthotopic implantation of human prostate cancer cell lines: a clinically relevant animal model for metastatic prostate cancer. Prostate 1997, 31(3):168-174. 10.1002/(SICI)1097-0045(19970515)31:3<168::AID-PROS4>3.0.CO;2-H, 9167768.
26. Kim SJ, Johnson M, Koterba K, Herynk MH, Uehara H, Gallick GE. Reduced c-met expression by an adenovirus expressing a c-met ribozyme inhibits tumorigenic growth and lymph node metastases of PC3-LN4 prostate tumor cells in an orthotopic nude mouse model. Cancer Res 2003, 9(14):5161-5170.
27. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004, 10(1):33-39. 10.1038/nm972, 14702632.
28. Mostaghel EA, Page ST, Lin DW, Fazli L, Coleman IM, True LD, Knudsen B, Hess DL, Nelson CC, Matsumoto AM, et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 2007, 67(10):5033-5041. 10.1158/0008-5472.CAN-06-3332, 17510436.
29. Huggins C, Hodges CV. Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002, 168(1):9-12. 10.1016/S0022-5347(05)64820-3, 12050481.
30. Curtin D, Jenkins S, Farmer N, Anderson AC, Haisenleder DJ, Rissman E, Wilson EM, Shupnik MA. Androgen suppression of GnRH-stimulated rat LHbeta gene transcription occurs through Sp1 sites in the distal GnRH-responsive promoter region. Mol Endocrinol 2001, 15(11):1906-1917. 10.1210/me.15.11.1906, 11682622.
31. Maeda A, Nakashiro K, Hara S, Sasaki T, Miwa Y, Tanji N, Yokoyama M, Hamakawa H, Oyasu R. Inactivation of AR activates HGF/c-Met system in human prostatic carcinoma cells. Biochem Biophy Res Commun 2006, 347(4):1158-1165.
32. Nakashiro K, Hara S, Shinohara Y, Oyasu M, Kawamata H, Shintani S, Hamakawa H, Oyasu R. Phenotypic switch from paracrine to autocrine role of hepatocyte growth factor in an androgen-independent human prostatic carcinoma cell line, CWR22R. Am J Pathol 2004, 165(2):533-540. 1618563, 15277227.
33. Tate A, Isotani S, Bradley MJ, Sikes RA, Davis R, Chung LW, Edlund M. Met-Independent Hepatocyte Growth Factor-mediated regulation of cell adhesion in human prostate cancer cells. BMC Cancer 2006, 6:197. 10.1186/1471-2407-6-197, 1559714, 16869958.
34. Agoulnik IU, Vaid A, Bingman WE, Erdeme H, Frolov A, Smith CL, Ayala G, Ittmann MM, Weigel NL. Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res 2005, 65(17):7959-7967.
35. Craft N, Shostak Y, Carey M, Sawyers CL. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat Med 1999, 5(3):280-285. 10.1038/6495, 10086382.
36. Kosharskyy B, Solban N, Chang SK, Rizvi I, Chang Y, Hasan T. A mechanism-based combination therapy reduces local tumor growth and metastasis in an orthotopic model of prostate cancer. Cancer Res 2006, 66(22):10953-10958. 10.1158/0008-5472.CAN-06-1793, 17108133.
37. Solban N, Selbo PK, Sinha AK, Chang SK, Hasan T. Mechanistic investigation and implications of photodynamic therapy induction of vascular endothelial growth factor in prostate cancer. Cancer Res 2006, 66(11):5633-5640. 10.1158/0008-5472.CAN-06-0604, 16740700.
38. Scatena CD, Hepner MA, Oei YA, Dusich JM, Yu SF, Purchio T, Contag PR, Jenkins DE. Imaging of bioluminescent LNCaP-luc-M6 tumors: a new animal model for the study of metastatic human prostate cancer. Prostate 2004, 59(3):292-303. 10.1002/pros.20003, 15042605.
39. Munshi N, Jeay S, Li Y, Chen CR, France DS, Ashwell MA, Hill J, Moussa MM, Leggett DS, Li CJ. ARQ 197, a novel and selective inhibitor of the human c-met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther 2010, 9(6):1544-1553. 10.1158/1535-7163.MCT-09-1173, 20484018.
40. Dai Y, Siemann DW. BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitro. Mol Cancer Ther 2010, 9(6):1554-1561. 10.1158/1535-7163.MCT-10-0359, 20515943.